A Short Acute Octreotide Test for Response Prediction of Long-term Treatment with Somatostatin Analogues in Acromegalic Patients

Abstract

The usefulness of the acute octreotide test in the selection of acromegalic patients for chronic somatostatin depot analogues treatment is controversial. The aim of the present study was to determine its accuracy for chronic response prediction, and the reliability of a short version of the classic 6-hour test. The data from 26 acromegalics (19 women, 7 men, mean age 52.6±13.1 years) studied with an acute octreotide test (6 hours sampling for GH measurement after octreotide 100 μg s. c.) were retrospectively analyzed. Eighteen of them followed chronic somatostatin depot analogues treatment for 12 months. GH nadir was always detected at 2 hours (mean decrease 75.9±24%). GH levels at 2 hours positively correlated with the other time-points (r_s 0.97, 0.98, 0.97, 0.96 at 3, 4, 5 and 6 h, respectively; p<0.0001). During chronic treatment with maximal effective dose for 12 months, 61% of the patients achieved IGF1 <3 SD and 22% reached IGF1 <2 SD. GH nadir correlated with IGF1 decrease at 12 months (r_s 0.76, p<0001). GH nadir of 9.2 ng/ml predicts IGF1 <3 SD with 82% sensitivity and 58% specificity (75% PPV, 67% NPV); for IGF1<2 SD, 75% sensitivity and 58% specificity are obtained for GH nadir 3.6 ng/ml, with 33% PPV and 89% NPV. Acute octreotide test reliably predicts response to long-term treatment; the short, 2-hour version is fully informative for therapeutic decisions in acromegalic patients.

Key words

acromegaly - octreotide - drug treatment - pituitary tumors

References

• 1 Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, MacConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.  J Clin Endocrinol Metab. 2002;  87 4554-4563
• 2 Freda PU. Somatostatin analogs in acromegaly.  J Clin Endocrinol Metab. 2002;  87 3013-3018
• 3 Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly.  J Clin Endocrinol Metab. 2006;  90 1856-1863
• 4 Balsa JA, Varela C, Lucas T, García-Uría J, Barceló B, Sancho-Rof JM. Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas.  Horm Metab Res. 2002;  34 435-440
• 5 Clemmons DR, Chihara K, Freda PU, Ho KKY, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.  J Clin Endocrinol Metab. 2003;  88 4759-4767
• 6 Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JC. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical ‘cure’.  Clin Endocrinol (Oxf). 1988;  29 411-420
• 7 Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly.  J Clin Endocrinol Metab. 1996;  81 2356-2362
• 8 Lindsay JR, MacConnell EM, Hunter SJ, MacCance DR, Sheridan B, Atkinson AB. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve “safe” growth hormone levels.  Pituitary. 2004;  7 139-144
• 9 Pokrajac A, Claridge AG, Shakoor SKA, Trainer PJ. The octreotide test dose is not a reliable predictor of subsequent response to somatostatin analogue therapy in patients with acromegaly.  Eur J Endocrinol. 2006;  154 267-274
• 10 Herder WW de, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, Lely AJ van der. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF1 normalization with Sandostatin LAR in acromegaly.  Eur J Endocrinol. 2005;  153 67-71
• 11 Granada ML, Murillo J, Lucas A, Salinas I, Llopis MA, Castells I, Foz M, Sanmartí A. Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population.  Eur J Endocrinol. 2000;  142 243-253
• 12 Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. Guidelines for acromegaly management.  J Clin Endocrinol Metab. 2002;  87 4054-4058
• 13 Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience.  Pituitary. 2005;  8 93-97
• 14 Reubi JC, Landoldt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.  J Clin Endocrinol Metab. 1989;  68 844-850
• 15 Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.  J Clin Endocrinol Metab. 2005;  90 6290-6295
• 16 Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.  Horm Res. 2004;  62 227-232
• 17 Halah FPB, Elias LLK, Martinelli CE, Castro C, Moreira AC. Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly.  Arq Bras Endocrinol Metabol. 2004;  48 245-252
• 18 Biermasz NR, Pereira AM, Smit JWA, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.  Growth Horm IGF Res. 2005;  15 200-206
• 19 Karavitaki N, Botusant I, Radian S, Coculescu M, Turner HE, Wass JAH. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.  Clin Endocrinol (Oxf). 2005;  62 282-288
• 20 Gilbert JA, Miell JP, Chambers SM, MacGregor AM, Aylwin SJ. The nadir growth hormone after an octreotide test predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.  Clin Endocrinol (Oxf). 2005;  62 742-747
• 21 Lely AJ van der, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johansson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.  Lancet. 2001;  358 1754-1759

Correspondence